{'fraction_non_alphanumeric': 0.03585739237645125, 'fraction_numerical': 0.02738107469433885, 'mean_word_length': 4.993534482758621, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 1, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Conditional Knockout of Integrin α2β1 in Murine Megakaryocytes Leads to Reduced Mean Platelet Volume

We have engineered a transgenic mouse on a C57BL/6 background that bears a floxed Itga2 gene. The crossing of this mouse strain to transgenic mice expressing Cre recombinase driven by the megakaryocyte (MK)-specific Pf4 promoter permits the conditional knockout of Itga2 in the MK/platelet lineage. Mice lacking MK α2β1 develop normally, are fertile, and like their systemic α2β1 knockout counterparts, exhibit defective adhesion to and aggregation induced by soluble type I collagen and a delayed onset to low dose fibrillar collagen-induced aggregation, results consistent with blockade or loss of platelet α2β1. At the same time, we observed a significant reduction in mean platelet volume, which is consistent with the reported role of α2β1 in MK maturation and proplatelet formation in vivo. This transgenic mouse strain bearing a floxed Itga2 gene will prove valuable to distinguish in vivo the temporal and spatial contributions of α2 integrin in selected cell types.


Introduction
The integrin a2b1 (VLA-2; GPIa-IIa, CD49b) is widely expressed on numerous cell types and binds specifically to type I collagen and decorin [1,2], but also to collagens types II-V and laminins 1 and 5 [3]. The a2 protein was first isolated from platelets where it mediates adhesion to extracellular matrix collagen and contributes to the initiation of platelet activation and hemostasis [4,5]. a2b1 also plays an important role in megakaryocyte (MK) maturation, where it mediates MK binding to collagen I in the bone marrow thereby delaying proplatelet formation through mechanisms dependent on Rho-ROCK and other pathways [6,7,8].
The analyses of a2b1 deficiency in two mouse models to date have utilized systemic Itga22/2 mice [9,10]. In both models, in vitro platelet responses initiated by soluble collagen were impaired, but no obvious in vivo hemostatic defects were observed. In one study, normal platelet counts were also reported for systemic Itga22/2 mice [10].
One problem of systemic knockout mouse models is that compensating effects within and between different cell lineages can obscure tissue-specific effects. This may be particularly true in the case of a ubiquitous receptor such as a2b1, which is expressed in the various cellular compartments of the circulation (platelets, mononuclear cells), the vasculature (endothelial cells, mural cells, fibroblasts) and the bone marrow (megakaryocytes, myeloid precursors, stromal cells). The conditional knockout of such ubiquitous proteins, using methods such as the Cre-Lox system, can help to distinguish the variety of effects contributed by these various cell types.
For these reasons, we engineered a transgenic mouse on a C57BL/6 background that bears a floxed Itga2 gene. The crossing of this mouse strain to transgenic mice expressing Cre recombinase driven by the MK-specific Pf4 promoter permits the conditional knockout of Itga2 in the MK/platelet lineage.
In this report, we evaluate selected functions and relevant physical characteristics of platelets from conditional MK Itga22/ 2 mice.

Ethics Statement
This study was conducted in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee of The Scripps Research Institute (Assurance of Compliance No. A3194-01) and CHOC Children's Hospital (Assurance of Compliance No. A3987-01).

Engineering of the loxP-Itga2 mouse
A targeting vector was designed to add loxP sites flanking exon 1, which contains 149 bp of the 39 UTR and the first 19 codons (Figure 1). The deletion of exon 1 had previously been shown to be sufficient to inactivate Itga2 [9]. The long and short arms were designed to avoid repetitive sequences using the online applica-tion RepeatMasker (http://www.repeatmasker.org/cgi-bin/ WEBRepeatMasker). Naturally occurring Apa1 and Sac2 sites in the long and short arms were used for cloning. The short arm and exon 1 were amplified from Bruce 4 ES cell gDNA, and the long arm was amplified from BAC PR23-448L13 (Children's Hospital Oakland Research Institute), using Phusion High-Fidelity DNA polymerase (Thermo Scientific, Inc., Vantaa, Finland). The floxed exon 1, the short arm and the long arm respectively were cloned into pBS-FRT-Neo-FRT (a gift from Dr. Uli Mueller, TSRI) in three stages. First, the floxed exon 1 (954 bp) was cloned directionally between Hind3 and Sma1 sites of the vector, thus introducing a novel Hind3 site to serve as a genotyping marker. Second, the short arm (2253 bp) was cloned in the Sac2 site. Finally, the long arm (4783 bp) was cloned directionally between Apa1 and Hind3 sites. The correct sequence was confirmed by Sanger sequencing. The plasmid was harvested using the EndoFree Maxiprep kit (Qiagen, Valencia, CA). Plasmid DNA (180 ug) was linearized with Apa1, precipitated with ethanol and submitted to the Mouse Genetic Core at TSRI for Bruce 4 ES cell electroporation. Stably transfected cells were selected by Neo resistance. A total of 304 Bruce 4 ES cell clones were screened for homologous insertion of the transgene by PCR across the short and the long arms using primer pairs P7/P8 and P9/P10 ( Table 1) and Hind3 restriction fragment length analyses.
Two Bruce 4 ES cell clones (#103 and #268) were injected into (BALB/c ByJ x B6(Cg)-Tyr,c-2J./J)F2 blastocysts, performed by the TSRI Mouse Genetics Core. From clone #103, ten chimeric mice were born, and two males with a black coat contribution greater than 50% were selected for further breeding. From clone #268, twenty-nine chimeric mice were born, and nine with a black coat contribution greater than 50% were selected for further breeding. In 9 of the 11 chimeric males, the presence of the correctly inserted long arm was confirmed by PCR. All eleven males were crossed to female albino B6 mice imported from The Jackson Laboratory (JAX; Bar Harbor, Maine) designated B6(Cg)-Tyr,c-2J./J (JAX #000058) to determine germ line transmission by coat color in the resulting pups. The presence of the floxed Itga2 gene in black pups was confirmed by PCR, and mice with the correct recombination were crossed to deletor (Flp) albino B6 mice (B6;SJL-Tg(ACTFL-Pe)9205Dym/J; JAX #003800; N13-N14 against albino B6 mice), so that the selection cassette flanked by the FRT sequences was removed, as confirmed by PCR, using primer pair P9/P11 ( Table 1). The resulting mice were intercrossed to obtain a2 flox/flox homozygotes, and genotype was confirmed by PCR with primer pairs P12/P13 and P14/P15 ( Figure 2). Our floxed-Itga2 strain has been deposited in The Jackson Laboratory collection and is designated C57BL/6-Itga2,tm1Tkun./J (JAX #018921).

Platelet parameters
Peripheral blood platelet counts and mean platelet volume (MPV) were analyzed as previously described [12], using a Cell-Dyn Emerald apparatus (Abbott Laboratories, Abbott Park, IL). Expression of platelet receptors, including GPIba, GPVI, and integrins a2b1, a5b1 and aIIbb3 was measured by flow cytometry as described [13], using a FACSCalibur flow cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ).

Western Blots
Tissue samples (lung, spleen) from a2 cKO mice and a2 flox/flox littermates were minced, homogenized in TRIS lysis buffer containing 2% SDS and protease inhibitors. Particulate and non-soluble material were removed by centrifugation, and soluble proteins from each source were separated by SDS-PAGE under reducing conditions and transferred to nitrocellulose membranes [14]. Platelet and mononuclear cells (MNC) were isolated from A) The targeting vector construction is depicted schematically to show positions of the key restriction sites used to clone exon1 flanked by loxP sites (middle), long arm (left) and short arm (right) DNA segments into the vector pBS-FRT-neo-FRT, which already contained the Neomycin-Kanamycin resistance marker flanked by FRT sequences, removable by Flp-recombinase. The positions of loxP and FRT sites are shown relative to exon 1 (E1). A unique Hind 3 restriction site was introduced next to the loxP sequence to facilitate the verification of a correct homologous recombination event in later stages. B) The screening strategy to identify ES cells with a correct recombination event. Two PCR reactions were employed, each utilizing one primer located within the natural a2 gene sequence beyond the end of the short (P8) or long (P9) arms, thus excluding amplification of random insertions. C) Genotyping strategy employed to detect removal of the Neomycin cassette by Flp-recombinase using primer pairs P12/P13 and P14/P15. Once homozygous mice were obtained, the correct location of the trans-gene was verified by PCR amplification of the entire region using primer pair P9/P11, each located in the natural Itga2 gene sequence beyond the long and short arms, followed by Hind3 restriction fragment length polymorphism analysis. Cre-recombinase mediated removal of the floxed exon 1 was confirmed by PCR using primer pair P12/P15. doi:10.1371/journal.pone.0055094.g001 heparanized peripheral blood, as described [13,15], and MNC were further cleared of platelets by absorption with polyclonal anti-mouse CD41 coupled to magnetic beads. Purified platelets and MNC were each solubilized in SDS buffer, proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. Membranes were blocked and incubated with polyclonal rabbit anti-mouse a2 antibody. Bound antibody was detected by HRP-conjugated anti-rabbit IgG and ECL (Amersham Biosciences) [14].

In Vitro Platelet Function Tests
The aggregation of platelets in platelet-rich-plasma (PRP) and the adhesion of platelets to soluble type I human collagen (purified in our laboratory) or bovine tendon collagen (fibrillar; Sigma-Aldrich, St. Louis, MO) were performed as described [13,16].

Tail bleeding times
In vivo haemostatic function was assessed by tail bleeding times, as described [17].

Statistical Analysis
Normally distributed variables were described by mean and standard deviation (SD), and the statistical differences were calculated by the t-test. A p-value #0.05 was considered statistically significant.
To evaluate platelet surface expression of a2b1, with reference to a second integrin a5b1, platelets in whole blood were analyzed by flow cytometry, as described [15], using anti-mouse integrin a2 (Sam.G4) and anti-mouse integrin a5 (Tap.A12) rat monoclonal antibodies (Emfrets, Germany) ( Figure 4). Anti-a5 is an appropriate control because the levels of a2b1 and a5b1 on platelets from the inbred C57BL/6 strain are comparable [15]. Platelets from PF4-Cre+;a2 flox/flox mice express very low to undetectable levels of platelet a2b1 but normal levels of platelet a5b1. On the other hand, platelets from PF4-Cre(neg); a2 flox/flox mice express levels of a2b1 or a5b1 equivalent to normal inbred C57BL/6 mice. At the same time, platelets from heterozygous PF4-Cre+; a2 flox/+ mice express roughly one-half the normal level   of a2b1 and normal levels of a5b1. An istotype identical, irrelevant nonoclonal IgG failed to bind above baseline with any mouse platelet source. Additional analyses of Pf4-Cre+;a2 flox/flox mice platelets confirmed the exclusive loss of a2b1, but normal expression of other receptors, namely aIIbb3, GPIba and GPVI, using rat monoclonal antibodies Leo.D2, Xia.G5 and Gon.C2, respectively (Emfrets) (not shown). These results confirm that the introduction of the loxP sites flanking exon 1 of Itga2 does not affect expression of integrin a2b1 on platelets and that the introduction of the PF4-Cre gene in vivo results in the unique excision of Itga2 exon 1 in megakaryocytes and a specific loss of expression of platelet a2b1.
Defective adhesion of a2 cKO platelets to soluble type I human collagen Platelets from f/f littermates adhere to type I human collagen, as expected, in the absence of the GPVI inhibitor antibody JAQ-1 ( Figure 5). The inhibition by JAQ-1 confirms the importance of GPVI in platelet adhesion to collagen type I under static conditions. At the same time, even in the absence of JAQ-1, platelets from heterozygous f/-littermates exhibited a reduction in adhesion that was statistically significant at 45 minutes (p,0.05) and completely abolished in the presence of JAQ-1, while platelets from 2/2 mice exhibited negligible adhesion even in the absence of JAQ-1. These results confirm the importance of a2b1 in platelet adhesion to soluble collagen and demonstrate that the in vitro platelet function of our 2/2 mice is equivalent to that observed for systemic a2-deficient mice [10].

Defective aggregation of a2 cKO mice by soluble collagen
The aggregation of platelets induced by soluble collagen has been previously shown to be abnormal in systemic a2or b1deficient mice [10,19]. Consistent with those findings, we observed that the aggregation of platelets from our 2/2 mice was abnormal relative to f/f littermates ( Figure 6A). Platelets from 2/2 mice showed a negligible response to soluble type I human collagen up to a concentration of 100 mg/ml. In contrast, for f/f littermates, half-maximal aggregation was obtained at a concentration ,5 mg/ml; for heterozygous f/2 littermates, ,7 mg/ml. Platelets from our 2/2 mice exhibited normal maximal aggregation in response to fibrillar collagen (not shown), as previously reported for systemic KO mice [9,10], although the lag time between addition of agonist and initiation of aggregation with low dose fibrillar collagen (1 mg/ml) was consistently delayed: for f/f mice, 27.365.8 sec (n = 4); for 2/2 mice, 41.567.7 sec (n = 4) (p,0.05). At a higher fibrillar collagen dose (10 mg/ml), the lag times were similar: 21.863.9 sec vs. 22.363.4 sec. Comparable findings have been obtained in the presence of a2b1-blocking antibodies [20] or in either systemic a2b1 KO [10] or b1 KO mice [19].   Normal tail bleeding times The effect of the conditional a2 knockout on the in vivo tail bleeding time (tBT) was also assessed. Although the difference was not statistically significant (p = 0.126), the tBT in 2/2 mice (208630 sec; n = 6) was slightly higher than that of f/f mice (178634 sec; n = 6) ( Figure 6B).

Discussion
Platelet count and mean platelet volume (MPV) are two fundamental properties of normal platelets that can have a significant impact on platelet function in vivo, and MPV is in an important risk factor for negative outcomes in coronary artery and cerebrovascular disease.
The genetic component of platelet size has been studied in humans taking advantage of inherited platelet disorders as well as genome-wide association studies, as recently reviewed [21]. An inverse association of the of ITGA2 rs28095 minor allele T with mean platelet volume in patients with acute coronary syndrome was observed, suggesting that a2 integrin plays a direct role in the regulation of mean platelet volume [12].
In the present study we demonstrate that the a2 integrin influences the platelet size, using a novel genetically engineered mouse model. After removal of the alpha2 integrin selectively from the megakaryocyte lineage a decreased platelet size was observed. The mechanistic explanation for the role of a2 integrin platelet size is likely to involve its contribution to megakaryocyte maturation within the bone marrow.
According to a widely-held theory of platelet biogenesis in the bone marrow, immature megakaryocytes migrate from their osteoblastic niche towards the vascular niche, where pro-platelets are formed and shed into the blood stream [22]. This theory has gained support from direct in vivo visualization by videomicroscopy in the bone marrow of the pro-platelet formation and platelet shedding by megakaryocytes, located in close contact with vascular endothelium [23]. Early on, it was determined that fibrillar collagen supports MK maturation and proplatelet formation in vitro [24]. a2b1 has been found to be critcally required for stress fiber formation in the maturing MK, which is considered an important process for proplatelet formation [25]. Recent experiments using retroviral vectors in a mouse model demonstrated a ligand-dependent down regulation of the activated a2 integrin during megakaryocyte maturation in a collagen rich environment [26]. Also, in WASp (Wiscott-Aldrich Syndrome protein)-deficient mice, a defect was demonstrated in the negative regulation of proplatelet formation mediated by the a2 integrin [27]. Furthermore, ANKRD26 mutations in patients with type 2 familial thrombocytopenia were associated with both reduced a2 integrin expression and decreased mean platelet volume [28].
Systemic murine Itga2 knockouts did not result in thrombocytopenia [9,10], which was interpreted to mean that a2b1 is not involved in MK and proplatelet formation, in contrast to the wealth of data from other laboratories showing that in the bone marrow niche, the binding of MK a2b1 to type I collagen and subsequent activation of the Rho-ROCK pathway delays proplatelet formation [6,7,8]. While our results in the conditional MK Itga2 knockout mouse confirm that a2b1 is probably not essential for MK development and platelet production, they are also consistent with the general conclusion that inhibition of MK a2b1 adhesion to collagen in the bone affects the timing of proplatelet formation reflected in decreased MPV. Unfortunately, neither of the previous studies of systemic knockout mice measured MPV.
The creation of the floxed-Itga2 mouse will now enable investigators to distinguish the tissue-specific effects of variation in a2b1 alone or in combination with other receptors by a variety of cells, including platelets, peripheral blood mononuclear cells, endothelial cells or smooth muscle (mural) cells. Given the ubiquitous expression of a2b1, there are many opportunities in which the study of conditional knockout mice will generate meaningful in vivo data. For example, a2b1 is expressed by activated neutrophils and mediates their translocation to the extravascular space. Constitutive knockout of neutrophil versus fibroblast or smooth muscle cell expression of a2b1 would generate a model to compare the relative contribution of each cell type to the processes of acute inflammation and wound healing [29]. Similar approaches could be employed to distinguish the contribution of a2b1 in vivo to tubular morphogenesis of epithelial structures [9], development of the renal tubular system [30], and tumorigenesis or metastasis of numerous cancer cell types [31,32].
In summary, we show that mice lacking MK a2b1 develop normally, are fertile, and like their systemic a2b1 KO counterparts, exhibit no significant defects in platelet function. These results corroborate prior findings in systemic a2b1 knockout mice and confirm that the absence of a2b1 in MK of those mice was largely if not exclusively responsible for the observed platelet phenotype. The only significant difference in our hands was a reduction in mean platelet volume, which is consistent with the reported involvement of a2b1 in MK maturation and rate of proplatelet formation in the bone marrow.

Author Contributions
Conceived and designed the experiments: DH TJK. Performed the experiments: DH YC TJK. Analyzed the data: DH YC DJN TJK. Contributed reagents/materials/analysis tools: DJN ZMR TJK. Wrote the paper: DH TJK.